Published on
The narrative that brand-name drugmakers manipulate the patent system to block lower-cost generics has gained traction in recent years. But the evidence doesn’t support that claim. In a new @IPWatchdog, Inc op-ed, Professor Lietzan examines the data — and explains why developing new versions of existing products isn’t patent abuse. It’s how innovation works in every industry. You can read the full piece here.